A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer

Pediatric Hematology and Oncology

Volumn 22, Issue 2, 2005, Pages 103-114

  Çorapçioglu, Funda ^a,b   Sarper, Nazan ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Cumhuriyet Mah   (Turkey)

Author keywords

Cancer; Emesis; Ondansetron; Orally disintegrating tablet

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; ONDANSETRON; PREDNISOLONE; PROCARBAZINE; SEROTONIN 3 ANTAGONIST; TIOGUANINE; TROPISETRON; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HISTIOCYTOSIS X; HODGKIN DISEASE; HUMAN; MALE; NONHODGKIN LYMPHOMA; ORALLY DISINTEGRATING TABLET; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINOBLASTOMA; SOFT TISSUE SARCOMA; TABLET DISINTEGRATION; TABLET FORMULATION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; ONDANSETRON; SOLUBILITY; TREATMENT OUTCOME; VOMITING;

EID: 14644416009     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010590896468     Document Type: Article

References (33)

1. Ettinger DS. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Semin Oncol. 1995;22:6-18.
2. Culy CR, Bhana N, Plosker GL. Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs. 2001;3:441-449.
3. Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology. 1992;49:279-285.
4. Safonova SA, Gershanovich ML, Punanov IuA, et al. [Evaluation of the anti-emetic effectiveness of two drug formulations of ondansetron in combined chemotherapy for children with malignant tumors] [Article in Russian]. Vopr Onkol. 1999;45:424-428.
5. White L, Daly SA, McKenna CJ, et al. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimen given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol. 2000;17:445-455.
6. Zhang P, Feng F, He Y, et al. [Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs] [Article in Chinese], Zhonghua Zhong Liu Za Zhi. 2002;24:504-507.
7. Lehoczky O, Udvary J, Pulay T. Freeze dried ondansetron: first observations with fast dissolving oral antiemetic Zofran Zydis for the prophylaxix of the cisplatin-induced emesis in gynecological cancer patients. Neoplasma. 2002;49:126-128.
8. Bleiberg H, Van Belle S, Paridaens R. Compassionate use of tropisetron in patients at high risk of sever emesis. Ann Oncol. 1993;4:43-45.
9. Ōzkan A, Yildiz I, Yūksel L, et al. Tropisetron (Navoban®) in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Jpn J Clin Oncol. 1999;29:92-95.
10. Uysal KM, Olgun N, Sarialioǧlu F. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients. Turk J Cancer. 1999;41:207-218.
11. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187-198.
12. Köseoǧlu V, Kürekci AE, Sarici U, et al. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr. 1998;157:806-810.
13. Stiakaki E, Savvas S, Lydaki E, et al. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol. 1999;16:101-108.
14. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
15. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol. 1995;6:805-810.
16. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer. 1994;30:1083-1088.
17. Marty M, Kleisbauer JP, Fournel P, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs. 1995;6:15-21.
18. Perez EA. Overview: oral granisetron (Kytril tablets): prophylaxis for chemotherapy induced nausea and vomiting. Semin Oncol. 1995;22:1-2.
19. Friedman CJ, Burris HA III, Yocom K, et al. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist. 2000:5:136-143.
20. Spector JI, Lester EP, Chevlen EM, et al. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy. Oncologist. 1998;3:432-438.
21. Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997:54:273-298.
22. Holdsworth MT, Raisch DW, Duncan MH, et al. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother. 1995;29:16-21.
23. Stevens RF. The role of ondansetron in paediatric patients: a review of three studies. Eur J Cancer. 1997;27:20-22.
24. Small BE, Holdsworth MT, Raisch DW, et al. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol. 2000;22:125-132.
25. Benoit Y, Hulstaert F, Vermylen C, et al. Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Med Pediatr Oncol. 1995;25:457-462.
26. Hachimi-Idrisis S, De Schepper J, Maurus R. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy. Eur J Cancer. 1993;29:854-856.
27. Pinkerton CR, Williams D, Wootton C, et al. 5-HT3 antagonist ondansetron-an effective outpatient antiemetic in cancer treatment. Arch Dis Child. 1990;65:822-825.
28. Alvarez O, Freeman A, Bedros A, Call SK, et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol. 1995;17:145-150.
29. Cohen IJ, Zehavi N, Buchwald I, et al. Oral ondansetron: an effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. Pediatr Hematol Oncol. 1995;12:67-72.
30. Komado Y, Matsuyama T, Takoa A, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukemia receiving emetogenic chemotherapy. Eur J Cancer. 1999;35:1095-1101.
31. Liaw CC, Wang CH, Chang HK, et al. Gender discrepancy observed between chemotherapy-induced emesis and hiccups. Support Care Cancer. 2001;9:435-441.
32. Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind randomized parallel study. J Clin Oncol. 1998;16:754-760.
33. 3 receptor antagonists for emetogenic chemotherapy. Oncol Nurs Forum. 2000;27:483-493.